A5047503586- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Systemic Lupus Erythematosus Research
- Lymphoma Diagnosis and Treatment
- Psoriasis: Treatment and Pathogenesis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Monoclonal and Polyclonal Antibodies Research
- Peripheral Neuropathies and Disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Inflammatory Myopathies and Dermatomyositis
- Tuberculosis Research and Epidemiology
- Medication Adherence and Compliance
- Musculoskeletal Disorders and Rehabilitation
- Pharmaceutical studies and practices
- Adolescent and Pediatric Healthcare
- Mycobacterium research and diagnosis
- Toxin Mechanisms and Immunotoxins
- Systemic Sclerosis and Related Diseases
- Migraine and Headache Studies
- Neuroscience of respiration and sleep
- Hemophilia Treatment and Research
Ministry of Social Affairs and Health
2018-2024
University of Helsinki
2000-2023
Helsinki University Hospital
2000-2023
Durham VA Medical Center
2022
University of North Carolina at Chapel Hill
2022
Emory University
2022
American College of Rheumatology
2022
Pfizer (United Kingdom)
2018-2021
Novartis (Switzerland)
2018-2021
Karolinska Institutet
2021
Because of the role tumor necrosis factor (TNF) in host defense, it was hypothesized that its inhibition might lead to an increased risk malignancies and infections. The objective our study assess incidence serious infections leading hospitalization among patients with rheumatoid arthritis (RA) receiving either TNF inhibitor or rituximab (RTX) therapy.The population identified from National Register for Biologic Treatment Finland hospital records Central Hospital conventional...
Objective. The aim of this research was to describe the effectiveness and drug survival tumor necrosis factor (TNF) inhibitors in treatment ankylosing spondylitis (AS) analyze effect concomitant with conventional disease-modifying antirheumatic drugs. Methods. Patients AS identified from National Register for Biologic Treatment Finland starting their first TNF inhibitor between July 2004 December 2011 were included. response measured as an improvement 50% (or 20 mm) after 6 months onset...
Efficacy of TNF inhibitors in the treatment RA assessed randomized controlled trials (RCTs) may not be fully comparable to routine care owing stringent inclusion criteria. The objective this study was observe effectiveness real-world patients and assess patients' potential eligibility for RCTs.RA starting a TNF-inhibitor between 2004 2014 were identified from National Register Biologic Treatment Finland, which is longitudinal observational cohort study. Effectiveness measured using ACR EULAR...
Under the auspices of European League Against Rheumatism (EULAR), a study group investigators representing biologic DMARD (bDMARD) registers was convened. The purpose this initial assessment to collect and compare cross section patient characteristics collate information on availability potential confounders within these registers.Baseline patients starting their first bDMARD in an arbitrary year (2008) for treatment RA, including demographic disease characteristics, drug details...
Falling asleep as a means of ending migraine attack was studied in 133 4-16-year-old children out-patient settings. Children registered 999 attacks headache diaries using visual analogue scale (VAS) 409 and five-face 590 attacks. The distribution maximal pain intensity similar on both scales; VAS 88% assigned grades between 63 100, the face 93% 4 or 5. fell during 33% (n = 329), 64% these within first hour 209). Of children, 68% 91) had fallen at least once an attack. more common under 8...
The aim of this study was to explore the cost-effectiveness biological DMARDs (bDMARDs) compared with conventional synthetic (csDMARDs) for RA using real-world data from Finnish registers.RA patients starting their first bDMARD and comparator csDMARDs during 2007-11 were obtained National register biologic treatments in Finland Jyväskylä Central Hospital patient records. Propensity score matching applied adjust differences between csDMARD users. Effectiveness measured quality-adjusted life...
Objectives: Large-scale observational cohorts may be used to study the effectiveness and rare side effects of biological disease-modifying anti-rheumatic drugs (bDMARDs) in ankylosing spondylitis (AS), but hampered by differences baseline characteristics disease activity across countries. We aimed explore research infrastructure five Nordic countries regarding bDMARD treatment AS.Method: This cohort was based on data from registries Denmark (DANBIO), Sweden (SRQ/ARTIS), Finland (ROB-FIN),...
To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA) using adalimumab as the main comparator.This was an observational, prospective cohort study. Patients SpA (clinical ankylosing spondylitis, nonradiographic axial SpA, or undifferentiated SpA) starting a TNFi during 2015-2018 were identified from 5 Nordic clinical rheumatology registries. Data on comorbidities...
Objective Although clinical trials support equivalence of originator products and biosimilars for etanercept infliximab, real-world studies among biologics-naïve patients with spondyloarthritis (SpA) are lacking. The objectives were to compare treatment retention in SpA starting either the product or a biosimilar infliximab etanercept, explore baseline characteristics these patients. Methods Patients (ankylosing spondylitis/non-radiographical axial SpA/undifferentiated SpA), as their...
Objective: To assess what proportion of patients with disease-modifying anti-rheumatic drug (DMARD)-naïve early rheumatoid arthritis (ERA) reach 28-joint Disease Activity Score (DAS28) remission over 1 year, and variability across clinics in Finland.Method: Patients DMARD-naïve newly diagnosed inflammatory were recruited. The three variables (DAS28-3) was compared sites. Repeated measures analysed using a mixed models approach appropriate distribution link function.Results: In total, 611...
Objective Interstitial lung disease (ILD) is one of the most common pulmonary manifestations rheumatoid arthritis (RA), but its prevalence has not been investigated in psoriatic (PsA). The role methotrexate (MTX) ILD development remains under debate. This study (1) compares incidences patients with RA or PsA initiating a first biologic disease-modifying antirheumatic drug (bDMARD) to that general population, and (2) investigates MTX comedication on incidence. Methods Patients were identified...
Objectives The objective of this study was to evaluate the cost-effectiveness abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors as compared with rituximab in Finnish rheumatoid arthritis patients, who have previously been treated TNF inhibitors. Methods A patient-level simulation model developed predict costs outcomes associated four biological drugs (abatacept, inhibitors) treatment arthritis. Following lack efficacy or adverse events, patients were switched another drug...
Abstract Objectives To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients psoriatic arthritis (PsA). Methods From the Nordic clinical rheumatology registers (CRR) here: SRQ/ARTIS (Sweden), DANBIO (Denmark), NOR-DMARD (Norway), ROB-FIN (Finland) and ICEBIO (Iceland) we identified PsA who started a first TNFi 2001–2017 (n = 9655). We not treated biologics from (i) CRR 14 809) (ii) national patient (PR, n 31 350). By linkage to registers,...
What is already known about this subject?► According to RA treatment recommendations, patients with a history of previous solid organ malignancy should be treated as without condition, although the level evidence low. does study add?► This large multinational register-based quantified proportion starting bDMARD who had prior (1-6%).This was significantly higher for rituximab (8-17%), demonstrating preference in patient population. How might impact on clinical practice?► There reluctancy use...
In axial spondyloarthritis (axSpA), switching between multiple biologic or targeted synthetic (b/ts-) DMARDs might indicate difficult-to-treat disease. We aimed to explore the occurrence of in routine care axSpA patients using various definitions, and identify associated clinical characteristics upon start first b/tsDMARD (baseline).Observational cohort study including with starting a first-ever 2009-2018 based on data from five registries (Denmark/Sweden/Finland/Norway/Iceland)....
Objective In rheumatoid arthritis (RA), evidence regarding the effectiveness of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients whose first-ever bDMARD was non–tumor necrosis factor inhibitor (TNFi) is limited. The objective this study therefore to assess outcome (non-TNFi: rituximab [RTX], abatacept [ABA], or tocilizumab [TCZ], separately; and TNFi) after failure non-TNFi as first bDMARD. Methods We identified with RA from 5 Nordic biologics registers who started...
Objective To compare incidences of neuroinflammatory events, including demyelinating disease (DML), inflammatory polyneuropathies (IPN) and multiple sclerosis (MS), in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA; psoriatic arthritis) starting a tumour necrosis factor inhibitor (TNFi), investigating whether monoclonal TNFi antibodies (other TNFis (oTNFis)) confer higher risk than etanercept. Methods This is an observational cohort study from the five Nordic countries...
<h3>Background</h3> There is little information on the effect of biological treatment incidence and outcomes joint replacement surgery. The results from a single centre in Brazil show reduction number total replacements that occurred simultaneously with induction biologic therapies, which line Japanese report [1,2]. Another study Sweden found while hip decreased, knee increased [3]. <h3>Objectives</h3> aim was to if drugs alters need for primary revision surgery or prosthesis survival...